Trials / Terminated
TerminatedNCT00832624
The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)
Open-label, Non Placebo-Controlled Study To Verify the Effect of Sitagliptin In Adult Patients With Type 2 Diabetes and Inadequate Glycemic Control
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
to assess the effect of treatment with Sitagliptin (MK0431) on HbA1c (Hemoglobin A1c) and the safety and tolerability of Sitagliptin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sitagliptin | Sitagliptin, 100 mg, 1 Tablet, once a day, for 18 weeks |
Timeline
- Start date
- 2008-11-26
- Primary completion
- 2009-09-02
- Completion
- 2009-09-02
- First posted
- 2009-01-30
- Last updated
- 2017-05-23
- Results posted
- 2010-10-11
Source: ClinicalTrials.gov record NCT00832624. Inclusion in this directory is not an endorsement.